8. Literaturverzeichnis

Achiron A, and Barak Y
Multiple Sclerosis-From Probable to Definite Diagnosis: A 7-Year Prospective Study
Arch Neurol 2000; 57:974–979

Amato MP, Ponziani G
A prospective study on the prognosis of multiple sclerosis

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report
J Neurol Neurosurg Psychiatry 1994; 57:897-902

Avasarala JR, Cross AH, Trotter JL
Oligoclonal Band Number as a Marker for Prognosis in multiple sclerosis
Arch Neurol 2001; 58:2044-2045

Bakshi R, Hutton GJ, Miller JR, Radue EW
The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis
Neurology 2004; 63:3-11

Banwell BL
Pediatric multiple sclerosis
Curr Neurol Neurosci Rep 2004; 4:245-252

Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance
Arch Neurol 2003; 60:1073-1081

Bartosik-Psujek H, Archelos JJ
Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG
J Neurol 2004; 251:414-420

Baum K, Nehring C, Schörner W, Girke W
Relations between MRI and CT findings, cerebrospinal fluid parameters and clinical features
Clin Neurol Neurosurg 1990; 92:49-55

Beer S, Rosler KM, Hess CW
Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria
J Neurol Neurosurg Psychiatry 1995; 59:152-159
Bergamaschi R, Tonietti S, Franciotta E, Candeloro E, Tavazzi E, Piccolo G, Romani A, Cosi V
Oligoclonal bands in Devic’s Neuromyelitis optica and multiple sclerosis: differences in repeated
cerebrospinal fluid examination
Multiple Sclerosis 2004; 10:2-4

Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F,
Reindl M
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first
demyelinating event
N Engl J Med 2003; 349:139-145

Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri P B, Capobianco M, Milano E,
Melis F, Giordana MT
Differential effects of three interferon betas on neutralising antibodies in patients with multiple
sclerosis: a follow up study in an independent laboratory

Bourahoui A, de Seze J, Gutierrze R, Onraed B, Hennache B, Ferriby D, Stojkovic T,
Vermersch P
CSF isoelectrofocusing in a large cohort of MS and other neurological diseases
European Journal of Neurology 2004; 11:525–529

Boutin B, Esquivel E, Mayer M, Chaumet S, Ponsot G, Arthuis M
Multiple sclerosis in children: report of clinical and paraclinical features of 19 cases
Neuropediatrics 1988; 19:118-123

Brass SD, Sridar Narayanan, Antel JP, Lapierre Y, Collins L, Arnold LD
Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status
Scale Score
Can J Neurol Sci 2004; 31:225-228

Brück W, Stadelmann C
Inflammation and degeneration in multiple sclerosis
Neuro Sci 2003; 24:265-267

Caroscio JT, Kochwa S, Sacks H, Makuku S, Cohen JA, Yahr MD
Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple
sclerosis
Arch Neurol 1986; 43:1129-1131

Identification of Epstein-Barr virus proteins as putative targets of the immune response
in multiple sclerosis

Cohen BA, Mikol DD
Mitoxantrone treatment of multiple sclerosis: Safety considerations
Neurology 2004; 63:28-32
Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW
The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group
Neurology 1998; 51: 885 – 887

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study
Lancet 2001; 357:1576–1582

Comi G
From inflammation to degeneration: the lessons of clinical trials
Neurol Sci 2003; 24:295–297

Confavreux C, Claudie C, Touraine F, Ventre JJ, Aimard G, Devic M
Plasma cells in cerebrospinal fluid and multiple sclerosis: diagnostic yield and clinicobiological correlations
Acta Neurol Scand 1986; 74:432-438

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study
Neurology 1996; 46:1607-1612

Confavreux C, Vukusic S
Natural history of multiple sclerosis: implications for counselling and therapy
Curr Opin Neurol 2002; 15:257-266

Confavreux C, Vukusic S, Adeleine P
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
Brain 2003; 126:770-782

O'Connor KC, Bar-Or A, Hafler DA
The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis

O'Connor P
The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS
Clin Ther 2003; 25:2865-2874

Correale J, de los Milagros Bassani Molinas M
Oligoclonal bands and antibody response in multiple sclerosis
J Neurol 2002; 249:375-389
Cross AH, Trotter JL, Lyons JA
B cells and antibodies in CNS demyelinating disease
J Neuroimmunol 2001; 112:1–14

Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ, Miller DH
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis
Ann Neurol 2002; 52:47-53

Davies G, Keir G, Thompson EJ
The significance of an intrathecal monoclonal immunoglobulin band: a follow-up study
Neurology 2003; 60:1163-1166

Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response
Brain 2001; 124:1325–1335

De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL
Chemical pathology of acute demyelinating lesions and its correlation with disability
Ann Neurol 1995; 38:901-909

Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis
J Neurol 2004; 251:542-547

Dyment DA, Ebers GC, Sadovnick AD
Genetics of multiple sclerosis
The Lancet Neurology 2004; 3:104-110

Fainardi E, Castellazzi M, Casetta I, Cultrera R, Vaghi L, Granieri E, Contini C
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms
J Neurol Sci 2004; 217:181-188

Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria.

Farrell MA, Kaufmann JC, Gilbert JJ, Noseworthy JH, Armstrong HA, Ebers GC
Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation
Neurology 1985; 35:212-218
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B
Randomised placebo-controlled trial of monthly intravenous immunoglobulin in relapsing-remitting multiple sclerosis
Lancet 1997; 349:589-593

Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis
J Neurol 1994; 241:132-137

Filippi M, Miller DH
Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis

Filippi M, Rocca MA, Comi G
The use of quantitative magnetic-resonance based techniques to monitor the evolution of multiple sclerosis

Franciotta D, Piccolo G, Guccia M, Bergamanschi R, Zardini E, Melzi d’Eril GV, Dondi E, Cosi V
Lack of both spinal fluid oligoclonal bands and complement 4A protein in an MS patient
Acta Neurol Scand 1994; 89:72-74

The significance of oligoclonal bands in multiple sclerosis in Japan: Relevance of immunogenetic backgrounds


Gadoth N
Multiple sclerosis in children
Brain Dev 2003; Jun, 25:229-232

Genain CP, Canella B, Hauser SL, Raine CS
Identification of autoantibodies associated with myelin damage in multiple sclerosis

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS
Neurology 2002; 59:909–913
Multiple sclerosis in childhood: clinical features of 149 cases
Mult Scler 1997; Feb, 3:43-46

Long term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests
J Neurol 1999; 246:770-775

Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis

Giovannoni G, Bever CT
Patients with clinically isolated syndromes suggestive of MS Does MRI allow earlier diagnosis?
Neurology 2003; 60: 6-7

Goffette S, Schluep M, Henry H, Duprez T, Sindic CJM
Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis
J Neurol Neurosurg Psychiatry 2004; 75:308-310

Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S
Disease modifying therapies in multiple sclerosis, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
Neurology 2002; 58:169-178

Hafler DA
Multiple sclerosis
J Clin Invest 2004; 113:788-794

Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J
Multiple sclerosis in childhood: report of 15 cases
Brain Dev 1991; 13:410-416

Hanefeld F
Multiple sclerosis in childhood
Curr Opin Neurol Neurosurg 1992; 5:359-363

Hawkins SA, McDonnell GV
Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors
J Neurol Neurosurg Psychiatry 1999; 67:148-152
Hein T, Hopfenmüller W
Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland
Nervenarzt 2000; 71:288-294

Hemmer B, Cepok S, Nessler S, Sommer N
Pathogenesis of multiple sclerosis: an update on immunology
Curr Opin Neurol 2002; 15:227-231

Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H
The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis
J Neuroimmunol 2000; 107:161-166

Izquierdo G, Angulo S, Garcia-Moreno JM, Gamero MA, Navarro G,
Gata JM, Ruiz-Pena JL, Paramo MD
Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS,
Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Boudette DN, Braiman J,
Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer
FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The
Multiple Sclerosis Collaborative Research Group (MSCRG)

Jongen PJH, Lamers KJB, Doesburg WH, Lemmens WAIG, Hommes OR
Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary
progressive multiple sclerosis
J Neurol Neurosurg Psychiatry 1997;63:446–451

Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR,
Weiner HL, Gasperini C, Filippi M
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes
in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis
Group
Lancet 1999; 353:964-969

Keegan BM, Noseworthy JH
Multiple sclerosis.

Kesselring J
Multiple Sklerose
Kohlhammer, Stuttgart 1997

Kleine TO, Zwerenz P, Graser C, Zöfel P
Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic
inflammation indices and TNF-α, IL-1β, IL-6, IL-8
Kornek B, Lassmann H
Neuropathology of multiple sclerosis—new concepts

Kurtzke JF
Rating neurological impairment in multiple sclerosis: an expended disability status scale (EDSS)
Neurology 1983; 33:1444-1452

Lassmann H, Brück W, Lucchinetti C
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.
Trends Mol Med 2001; 7:115–21

A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions.
Brain 2003; 126:1347-1357

Lee KH, Hashimoto SA, Hooge JP, LF Kastrukoff, JJ Oger, DK Li, Paty DW
Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Neurology 1991; 41:657-660

Link H, Tibbling G
Principles of albumin and IgG analysis in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis

Lolli F, Halawa I, Link H
Intrathecal IgG synthesis in multiple sclerosis: comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG
J Neurol 1981; 224:159-169

Lublin FD, Reingold SC
Defining the clinical course of multiple sclerosis: results of an international survey
Neurology 1996; 46:907-911

Lucchinetti CF, Brück W, Rodriguez M, Lassmann H
Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis
Brain Pathol 1996; 6:259-274

Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination
Ann Neurol 2000; 47:707-717

Lunding J, Midgard R, Vedeler CA
Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index
Lycke JN, Karlsson JE, Andersen O, Rosengren LE
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
J Neurol Neurosurg Psychiatry 1998; 64:402-404

Mandler RN, Davies LE, Jeffery DR, Kornfeld M
Devic’s neuromyelitis optica: a clinicopathological study of 8 patients
Ann Neurol 1993; 34:162-168

Martinez-Yélagos A, Saiz A, Sanchez-Valle A, Casado RV, Ramon JM, Graus F, Arbizu T
14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis
Neurology 2001; 57:722-724

Martinez-Yelamos Antonio, Albert Saiz, Jordi Bas, Juan Jose Hernandez, Francesc Graus, Txomin Arbizu
Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early
relapsing-remitting multiple sclerosis
Neuroscience Letters 2004; 363:14–17

Mata S, Lolli F, Soderstrom M, Pinto F, and Link H
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a
Multiple Sclerosis 1999; 5:379-388

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on
the diagnosis of Multiple Sclerosis
Ann Neurol 2001; 50:121–127

McLean BN, Luxton RW, Thompson EJ
A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected
neurological disease using isoelectric focusing and the log IgG-index
Brain 1990; 113:1269–1289

Mesaros S, Drulovic J, Levic Z
Clinical characteristics and neurophysiological findings in patients with multiple sclerosis without
oligoclonal IgG in cerebrospinal fluid
Srp Arh Celok Lek 2003; 131:122-126

Miller JR
The Importance of Early Diagnosis of Multiple Sclerosis
J Manag Care Pharm 2004; 10(Suppl 2):4-11

Mohr DC, Hart SL, Julian L, Cox D, Pelletier D
Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis
Moller JR, Johnson D, Brady RO, Tourtellotte WW, Quarles RH
Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients

Multiple Sklerose-Therapie-Konsensus-Gruppe (MSTKG)
Immunmodulatorische Stufentherapie der multiplen Sklerose
Nervenarzt 2001; 72:150-157

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG
Multiple sclerosis

Olsson JE, Link H, Muller R
Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: disability, duration and age of onset

O’Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DPE, Thompson EJ, McDonald WI, Miller DH
Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica
J Neurol Neurosurg Psychiatry 1996; 60:382-387

O’Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH
The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up
Brain 1998; 121:495–503

Paolino E, Fainardi E, Ruppi P, Tola MR, Casetta I, Monetti VC, Granieri E, Carreras M
A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis
J Neurol Neurosurg Psychiatry 1996; 60:572-575

Perini P, Calabrese M, Biasi G, Gallo P
The clinical impact of interferon beta antibodies in relapsing-remitting MS
J Neurol 2004; 251:305–309

Pinhas-Hamiel O, Sarova-Pinhas I, Achiron A
Multiple sclerosis in childhood and adolescence: clinical features and management
Paediatric Drugs 2001; 3:329-336

Pirrttilä T, Nurmikko T
CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis
Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weinshenker BG, Noseworthy J, and Rodriguez M,
Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-up Study

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW
New diagnostic criteria for multiple sclerosis: guideline for research protocols
Ann Neurol 1983; 13:227-231

Poser CM, Brinar VV
Diagnostic criteria for multiple sclerosis
Clin Neurol Neurosurgery 2001; 103:1-11

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
Lancet 1998; 352:1498–1504

Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis
Lab Invest 2003; 83:1081-1088

Ramsaransing G, Maurits N, Zwanikken C, De Keyser J
Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review
Mult Scler 2001; 7:345-347

Reiber H, Felgenhauer K
Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system
Clin Chim Acta 1987; 163:319-328

Reiber H
Untersuchungen des Liquors zur Diagnose neurologischer Erkrankungen
In: Holzgraefe M, Reiber H, Felgenhauer K (Hrsg.) Labordiagnostik von Erkrankungen des Nervensystems
Erlangen, Perimed Fachbuch-Verl.-Ges.1988; S. 35-50

Reiber H, Ungefehr S, Jacobi C
The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis
Mult Scler 1998; 4:111-117

Early prognostic factors for disability in multiple sclerosis, a European multicenter study
Acta Neurol Scand 1992; 85:212-218
Rossman H
Neutralizing Antibodies to Multiple Sclerosis Treatments
J Manag Care Pharm 2004; 10(suppl S-b):12-18

Rovaris M, Filippi M
Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis
Curr Opin Neurol 1999; 12:337–344

Runmarker B, Anderson O
Prognostic factors in multiple sclerosis incidence cohort with twenty five years of follow up
Brain 1993; 116:117-134

Sadatipour BT, Greer JM, Pender MP
Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis
Ann Neurol 1998; 44:980-983

Sadovnick A, Ebers G, Dyment D, Risch N and Canadian Collaborative Study Group
Evidence for genetic basis of multiple sclerosis
Lancet 1996; 347:1728–1730

Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings
Mult Scler 2003; 9:39-43

Satoh J, Yukitake M, Kurohara K, Takashima H, Kuroda Y
Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis
J Neurol Sci 2003; 212:11-20

Schröder M
MUSIS 2.0 - Multiple Sclerosis Information System: An easy-to-use-database to improve the care of patients with multiple sclerosis
Mult Scler 1999; 5:299-301

Selcen D, Anlar B, Renda Y
Multiple sclerosis in childhood: report of 16 cases
Eur Neurol 1996; 36:79-84

Sellebjerg F, Christiansen M, Rasmussen LS, Jaliachvili I, Nielsen PM, Fredriksen JL
The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae
Eur J Neurol 1996; 3:548-559
Sellebjerg F, Jensen CV, Christiansen M
Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis

Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F, Bellacosa A, Ceccarelli A, Pavone I, Livrea P
Course and prognosis in early-onset MS: comparison with adult-onset forms
Neurology 2002; 59:1922-1928

Sindern E, Haas J, Stark E, Wurster U
Early onset MS under the age of 16: clinical and paraclinical features

Söderström M, Ya-Ping J, Hillert J, Link H
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings
Neurology 1998; 50:708-714

Söderström M
Multiple sclerosis: rationale for early treatment
Neurol Sci 2003; 24:298–300

Sonnenberg R
Klinik, Kernspintomographiebefunde und Liquorbefunde bei der Multiplen Sklerose
Hannover, Med. Hochsch. Diss. 1996

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
Lancet 2003; 362:1184-1191

Stendahl-Brodin L, Link H
Relation of benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid
J Neurol Neurosurg Psychiatry 1980; 43:102-105

Swanborg RH, Whittum-Hudson JA, Hudson AP
Infectious agents and multiple sclerosis--are Chlamydia pneumoniae and human herpes virus 6 involved?
J Neuroimmunol 2003; 136:1-8

Thompson AJ, Hutchinson M, Martin EA, Mansfield M, Whelan A, Feighery C
Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course
J Neurol Neurosurg Psychiatry 1985; 48:989-994
Thompson AJ, Polman C, Miller D, McDonald WI, Brochet B, Filippi M, Montalban X, De Sa J
Primary progressive multiple sclerosis
Brain 1997; 120:1085–1096

Tintore M, Rovira A, Brieva L, et al.
Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging
criteria to predict conversion to CDMS
Mult Scler 2001; 76:359-363

Tsai JC, Gilden DH
Chlamydia pneumoniae and multiple sclerosis: no significant association
Trends Microbiol 2001; 9:152-154

Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in multiple sclerosis
Neurology 2002; 59:555-559

Intrathecal IgM Synthesis is a prognostic factor in multiple sclerosis
Ann Neurol 2003; 53:222-226

Early differential diagnosis of multiple sclerosis using a new oligoclonal banding test
Arch Neurol 2005; 62:574-577

Vukusic S, Confavreux C
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis
J Neurol Sci 2003; 206:135-137

Walderveen MAA, van Barkhof F, Hommes OR, Polman CH, Tobi H, Freqin STFM, Valk J
Correlating MRI and clinical disease activity in multiple sclerosis: Relevance of hypointense
lesions on short-TR/short-TE (T1 weighted) spin-echo images
Neurology 1995; 45:1684-1690

Walker RWH, Thompson EJ, McDonald WI
Cerebrospinal fluid in multiple sclerosis: relationship between immunoglobulins, leucocytes and
clinical features
J Neurol 1985; 232:250-259

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis
Lancet 2003; 361:2036-2043
Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC
The natural history of multiple sclerosis: a geographically based study I: clinical course and
disability
Brain 1989; 112:133–146

Wurster U
Elekrophoreseverfahren- Nachweis und Bedeutung von oligoklonalen Banden
In: Zettl U.K., Lehmitz R., Mix E. (Hrsg.): Klinische Liquordiagnostik

Yao Song-Yi, Stratton CW, Mitchell WM, Sriram S
CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens
Neurology 2001; 56:1168–1176

Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE
Nuclear magnetic resonance imaging of the brain in multiple sclerosis
Lancet 1981; 8255:1063-1066

The significance of serum oligoclonal bands in neurological diseases
J Neurol Neurosurg Psychiatry 1993; 56:32-5

Zeman AZ, Kidd D, Mc Lean BN, Kelly MA, Francis DA, Miller DH, Kendall BE, Rudge P,
Thompson EJ, McDonald WI
A study of oligoclonal band negative multiple sclerosis
J Neurol Neurosurg Psychiatry 1996; 60:27-30